Skip to main content

Table 1 Clinical information of patients

From: Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay

Category

Non-cancerous

Benign ovarian condition

Early stage serous ovarian cancer

Late stage serous ovarian cancer

Total

n

18

18

16

17

69

Age range (median)

50–83 (62.5)

36–81 (49)

42–83 (61)

53–75 (65)

36–83 (60)

Race (%)

     

 Caucasian

5

17

13

17

52 (75.4%)

 African American

1

   

5 (7.2%)

 Unidentified

12

   

12 (17.4%)

Stage I

  

10

  

Stage II

  

6

  

Stage III

   

15

 

Stage IV

   

2

 

CA125 range (median)*

0–69 (1.55)

6–413 (14.5)

32–22780 (108)

124–3417 (584)

 
  1. *CA125 levels were measured as U/mL